Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(−receptor) antibodies

Terhart, Maria; Mecklenburg, Jasper; Neeb, Lars; Overeem, Lucas Hendrik; Siebert, Anke; Steinicke, Maureen; Raffaelli, Bianca; Reuter, Uwe

doi:10.1186/s10194-021-01368-7

Table 2 Mean total scores of all questionnaires and the differences between the time points

From: Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(−receptor) antibodies

	V1	V2	V3	Difference V1-V2	Difference V1-V3	p-values
HIT-6 All Patients	59.69 ± 6.90	62.13 ± 6.68	63.38 ± 6.16	2.44 ± 6.98	3.69 ± 6.21	p < 0.001 V1 vs. V2 p = 0.006 V1 vs. V3 p < 0.001 V2 vs. V3 p = 0.568
HIT-6 CGRP-receptor mAb group	60.72 ± 5.61	63.41 ± 7.14	65.14 ± 4.04	2.69 ± 6.95	4.41 ± 6.01	p < 0.001 V1 vs. V2 p = 0.091 V1 vs. V3 p < 0.001 V2 vs. V3 p = 0.229
HIT-6 CGRP mAb group	58.75 ± 7.85	60.97 ± 6.11	61.78 ± 7.29	2.22 ± 7.11	3.03 ± 6.42	p = 0.022 V1 vs. V2 p = 0.086 V1 vs. V3 p = 0.062 V2 vs. V3 p > 0.999
EQ-5D-5L All Patients	0.85 ± 0.17	0.77 ± 0.18	0.77 ± 0.20	−0.07 ± 0.19	−0.07 ± 0.18	p = 0.001 V1 vs. V2 p = 0.008 V1 vs. V3 p = 0.013 V2 vs. V3 p > 0.999
EQ-5D-5L CGRP-receptor mAb group	0.85 ± 0.18	0.77 ± 0.17	0.77 ± 0.19	−0.08 ± 0.21	−0.09 ± 0.18	p < 0.001 V1 vs. V2 p = 0.002 V1 vs. V3 p = 0.002 V2 vs. V3 p > 0.999
EQ-5D-5L CGRP mAb group	0.84 ± 0.16	0.77 ± 0.20	0.78 ± 0.21	−0.07 ± 0.17	−0.06 ± 0.18	p = 0.485
PCS-12 All Patients	39.18 ± 9.70	35.74 ± 9.02	35.14 ± 8.98	−3.44 ± 8.39	−4.04 ± 7.90	p = 0.005 V1 vs. V2 p = 0.030 V1 vs. V3 p = 0.013 V2 vs. V3 p > 0.999
PCS-12 CGRP-receptor mAb group	38.43 ± 9.06	35.07 ± 8.41	33.64 ± 8.06	− 3.36 ± 7.94	−4.79 ± 7.00	p = 0.002 V1 vs. V2 p = 0.31 V1 vs. V3 p = 0.005 V2 vs. V3 p > 0.999
PCS-12 CGRP mAb group	39.86 ± 10.34	36.35 ± 9.63	36.50 ± 9.67	− 3.51 ± 8.90	−3.36 ± 8.69	p = 0.464
MCS-12 All Patients	43.95 ± 10.33	41.44 ± 11.43	41.22 ± 11.21	−2.51 ± 8.46	−2.73 ± 9.04	p = 0.003 V1 vs. V2 p = 0.089 V1 vs. V3 p = 0.003 V2 vs. V3 p = 0.832
MCS-12 CGRP-receptor mAb group	44.26 ± 9.85	40.80 ± 11.83	40.42 ± 10.27	−3.46 ± 8.13	−3.83 ± 8.33	p = 0.066
MCS-12 CGRP mAb group	43.68 ± 10.90	42.02 ± 11.20	41.95 ± 12.13	−1.66 ± 8.79	−1.73 ± 9.66	p = 0.041 V1 vs. V2 p = 0.401 V1 vs. V3 p = 0.044 V2 vs. V3 > 0.999

Data for all patients and both subgroups (CGRP-receptor mAb and CGRP mAb group). Data is expressed as mean ± standard deviation. The first p-value stated is derived from the Friedman test. The following p-values are derived from post-hoc pairwise comparisons with Bonferroni correction. V1 = time of last injection, V2 = 8 weeks after last injection, V3 = 16 weeks after last injection.

Back to article page

ISSN: 1129-2377

Contact us

Submission enquiries: journalsubmissions@springernature.com

The Journal of Headache and Pain

Contact us